A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of M5049 Administered Orally in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs M-5049 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck KGaA
- 02 Dec 2019 Status changed from recruiting to completed.
- 01 Apr 2019 Planned End Date changed from 7 May 2019 to 31 Jul 2019.
- 01 Apr 2019 Planned primary completion date changed from 7 May 2019 to 31 Jul 2019.